Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | LSS | P48449 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CCKAR | P32238 | 1/20 | 0.38 |
| ▸ | CCKBR | P32239 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6318597 | 1.00 | KDR (0.43) | KDRLSSRXFP1ROCK2GAA | |
| SCHEMBL6322247 | 0.89 | KMT2A (0.40) | ROCK2KDM4ECCKBR | |
| SCHEMBL6322253 | 0.89 | KMT2A (0.40) | ROCK2KDM4ECCKBR | |
| SCHEMBL6327035 | 0.89 | LSS (0.48) | KDRLSSROCK2CCKBRTMEM97 | |
| SCHEMBL6327539 | 0.89 | LSS (0.48) | KDRLSSROCK2CCKBRTMEM97 | |
| SCHEMBL6323528 | 0.89 | IDO1 (0.40) | KDRLSSROCK2 | |
| SCHEMBL6323531 | 0.89 | IDO1 (0.40) | KDRLSSROCK2 | |
| SCHEMBL30979384 | 0.89 | IDO1 (0.40) | KDRLSSROCK2 | |
| SCHEMBL4487046 | 0.87 | LSS (0.44) | LSSRXFP1ROCK2KDM4ETMEM97 | |
| SCHEMBL4487048 | 0.87 | LSS (0.44) | LSSRXFP1ROCK2KDM4ETMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855710-B2 | Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | CDK1, CDK2, CDK3 | KDR 448/4885LSS 3807/4885RXFP1 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.